Revvity Inc

Revvity Inc(RVTY)股票分析

$154.710

+2.630 (+1.70%)收盘时

Loading chart…
最高
156.860
开盘
151.910
成交量加权均价
153.47
成交量
2.37M
市值
13.04B
最低
148.830
成交额
363.62M
企业价值/息税折旧摊销前利润(TTM)
21.21

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

AI 分析 of Revvity Inc (RVTY)

买入

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

估值指标

Revvity Inc(RVTY)当前预期市盈率为 24.15,5 年平均预期市盈率为 22.13。

预期市盈率

合理
5 年均值 P/E
22.13
当前P/E
24.15
高估
25.11
低估
19.14

预期 EV/EBITDA

高估
5 年均值 EV/EBITDA
18.11
当前EV/EBITDA
21.21
高估
20.56
低估
15.66

预期市销率

高估
5 年均值 P/S
4.58
当前P/S
5.75
高估
5.29
低估
3.87

Alphio AI 对 RVTY 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%RVTY

$80.72

情景价格

基

基准

基准 · 50%RVTY

$80.47

情景价格

悲

悲观

悲观 · 25%RVTY

$65.23

情景价格

持有 RVTY 的大户

C

Campbell & Company, LP

+ 持有RVTY

+8.93%

3个月收益率

E

EdgePoint Investment Group Inc.

+ 持有RVTY

+4.51%

3个月收益率

M

Meridiem Capital Partners LP

+ 持有RVTY

+4.17%

3个月收益率

V

Vaughan Nelson Investment Management, L.P.

+ 持有RVTY

+2.68%

3个月收益率

P

Port Capital LLC

+ 持有RVTY

-1.53%

3个月收益率

事件时间线

2026-09-24 (ET)

10:00:00

Everpure Stock Rises $20.86 to $130.51

08:30:00

Revvity Launches GSP T1D 3plex Detection Kit

2026-09-15 (ET)

10:00:00

Skyworks and Others See Notable Stock Gains

2026-09-09 (ET)

06:30:00

Revvity Acquires French Biotech Company HCD

2026-08-04 (ET)

06:30:00

Company to Divest Immunodiagnostics Business in China

资讯

RVTY 常见问题 —— 由 Alphio AI 解答

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易